Amphetamine Stimulant Prodrug denied for failing step therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for amphetamine stimulant prodrug are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Applies Step-Therapy Requirements to Amphetamine Stimulant Prodrugs

Blue Cross Blue Shield uses step-therapy (also called "fail-first") protocols for amphetamine prodrug stimulants, requiring documentation that a patient has tried one or more lower-tier stimulant formulations before the prodrug will be authorized. The denial does not reflect a clinical judgment that the prodrug is inappropriate — it reflects that the claims record or submitted documentation does not yet demonstrate the required prior trials. Incomplete documentation of prior steps is the single most common reason step-therapy appeals succeed on internal review.

## Why This Denial Is Appealable

Step-therapy denials are adverse benefit determinations under ERISA §503 and ACA §2719. Many states have enacted step-therapy reform laws that explicitly require insurers to grant exceptions when a required step drug is contraindicated, previously failed, or clinically inappropriate — and these laws often set short decision timelines. Even without a state law, the federal external-review pathway gives an IRO the authority to override a step-therapy requirement when the evidence supports it. External review must typically be requested within approximately four months of the denial notice.

## The Concrete Appeal Process

1. Identify which step(s) BCBS requires. Request the complete step-therapy protocol in writing. 2. Determine if any step was already completed. Pharmacy records from other plans, prior insurers, or cash-pay prescriptions all count — gather them. 3. If a step is contraindicated or clinically inappropriate: Have the prescriber document this explicitly, citing chart-specific facts (not generic statements). 4. File the internal appeal with a comprehensive step-documentation packet. 5. Invoke your state's step-therapy exception law if applicable — include the statutory citation in your appeal letter. 6. External review if the internal appeal fails.

## Documentation to Gather

• Prior stimulant trial records: For each required step drug — agent name, start date, stop date, reason for stopping (inefficacy, adverse effect, or contraindication). Pharmacy fill history plus chart notes are the gold standard.
• Explanation of why the required step is inadequate: If the patient never took the step drug, explain why it is clinically inappropriate for this patient specifically.
• Prescriber medical-necessity letter: Addresses each step requirement and explains the clinical rationale for bypassing or having completed it.
• Diagnosis and severity documentation: Step-therapy exception decisions are strengthened when the underlying diagnosis is unambiguous and functional impairment is well documented.

## Criteria-Mapping Strategy

Obtain BCBS's step-therapy criteria for this drug class and the FDA label. Build a table: each required step in the left column; evidence of completion or exception grounds in the right column. If any step was completed outside the current BCBS plan, include pharmacy printouts or records from the prior insurer. Reviewers grant step-therapy exceptions most readily when every required step is addressed — leaving any step unanswered invites a blanket uphold.